A year of generic PrEP could recoup its own cost within five years if effectiveness is high, Public Health England model finds
No evidence of reduced efficacy or increased side-effects when patients switch to generic drugs, comparison study finds
Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows
Switching from Atripla to generic-containing regimens can produce large cost savings
Tests of online PrEP purchases by London clinic find no fakes, and adequate drug levels
New $90-$90-$90 target needed for global viral hepatitis, HIV and TB treatment
Dutch model finds PrEP for high-risk gay men is cost-effective at current prices and cost-saving at generic prices
Generic antiretrovirals could save NHS £1.25 billion over 5 years, study finds
